Daiwa Securities Group
FDMT icon

Daiwa Securities Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Daiwa Securities Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,370
Closed -$48K – 1273
2025
Q4 		$48K Buy
6,370
+6,186
+3,362% +$62.8K ﹤0.01% 1117
2025
Q3 		$2K Hold
184
– – ﹤0.01% 1268
2025
Q2 		$1K Sell
184
-9,394
-98% -$33K ﹤0.01% 1260
2025
Q1 		$31K Sell
9,578
-343
-3% -$1.62K ﹤0.01% 1051
2024
Q4 		$55K Buy
9,921
+9,737
+5,292% +$76.4K ﹤0.01% 1058
2024
Q3 		$2K Hold
184
– – ﹤0.01% 1217
2024
Q2 		$4K Sell
184
-5,390
-97% -$135K ﹤0.01% 1213
2024
Q1 		$178K Sell
5,574
-298
-5% -$7.6K ﹤0.01% 1002
2023
Q4 		$119K Buy
5,872
+1,110
+23% +$14.6K ﹤0.01% 994
2023
Q3 		$61K Hold
4,762
– – ﹤0.01% 1051
2023
Q2 		$86K Buy
4,762
+4,632
+3,563% +$85.3K ﹤0.01% 1030
2023
Q1 		$2K Hold
130
– – ﹤0.01% 1214
2022
Q4 		$3K Buy
130
+36
+38% +$556 ﹤0.01% 1192
2022
Q3 		$1K Hold
94
– – ﹤0.01% 1286
2022
Q2 		$1K Hold
94
– – ﹤0.01% 1287
2022
Q1 		$1K Hold
94
– – ﹤0.01% 1307
2021
Q4 		$2K Buy
+94
New +$2.3K ﹤0.01% 1281

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Daiwa Securities Group's FDMT Position: Q1 2026 in Review

Daiwa Securities Group sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 6,370 shares — an estimated $48K sold.

Daiwa Securities Group first reported a position in FDMT in Q4 2021 and held it in 17 quarters. The position peaked at $178K in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Daiwa Securities Group reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 6,370 4D Molecular Therapeutics shares in Q1 2026, an estimated $48K.
  • Daiwa Securities Group first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's 4D Molecular Therapeutics position peaked at $178K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.